Eventually getting into its stride
05/02/26 -"The Q4 25 performance exceeded expectations, ensuring that GSK delivered on the higher end of the 2025 guidance. HIV, Respiratory, Immunology and Oncology were the key growth drivers, while Vaccines ..."
Pages
66
Language
English
Published on
05/02/26
You may also be interested by these reports :
05/02/26
The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they ...
05/02/26
The Q4 25 performance exceeded expectations, ensuring that GSK delivered on the higher end of the 2025 guidance. HIV, Respiratory, Immunology and ...
04/02/26
The Q4 performance, even though subdued, ensured that Novartis met the management’s 2025 guidance. Healthy Q4 growth across most key areas was ...
04/02/26
Even though the Q4 performance ensured that Novo delivered on the lowered 2025 expectations, the markets seem frustrated with the 2026 outlook, ...